Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis.

Zhaolun CaiYiqiong YinYuan YinChaoyong ShenJian WangXiaonan YinZhixin ChenYe ZhouBo Zhang

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2018)

S-1-based chemotherapy and XELOX are likely to be the most effective adjuvant treatments for patients with resected gastric cancer. 5-FU alone provided little survival benefits as compared with surgery alone. Further clinical trials may be required to investigate S-1-based and XELOX-based adjuvant treatment strategies.

Keyphrases

early stage
clinical trial
lymph node
minimally invasive
squamous cell carcinoma
radiation therapy
free survival
surgical site infection